Dysplasia of cervix uteri
Chapter 14:Diseases of the genitourinary system
ICD-10 N87 is a billable code used to indicate a diagnosis of dysplasia of cervix uteri.
Dysplasia of the cervix uteri refers to abnormal changes in the cells on the surface of the cervix, which can be precursors to cervical cancer. This condition is often detected through routine Pap smears, which identify atypical squamous cells. Cervical dysplasia is categorized into three grades: mild (CIN 1), moderate (CIN 2), and severe (CIN 3), with the latter being the most concerning due to its higher risk of progression to invasive cancer. The etiology of cervical dysplasia is primarily linked to persistent infection with high-risk strains of human papillomavirus (HPV). Other risk factors include smoking, immunosuppression, and long-term use of oral contraceptives. Management of cervical dysplasia may involve monitoring, surgical interventions such as loop electrosurgical excision procedure (LEEP), or conization, depending on the severity and patient factors. Accurate coding for dysplasia is crucial for appropriate treatment planning and follow-up care, as well as for tracking population health trends related to cervical cancer prevention.
Detailed pathology reports, treatment plans, and follow-up notes.
Routine Pap smear results indicating dysplasia, follow-up after treatment for dysplasia.
Ensure accurate grading of dysplasia is documented to guide treatment.
Comprehensive cancer staging and treatment response documentation.
Management of patients with severe dysplasia or cervical cancer.
Coordination with pathology for accurate staging and treatment planning.
Used for routine screening and diagnosis of cervical dysplasia.
Document the reason for the Pap smear and any follow-up actions.
Gynecologists should ensure that the results are clearly linked to the diagnosis.
Performed when severe dysplasia is diagnosed.
Document the extent of the lesion and the procedure performed.
Oncologists should coordinate with pathology for accurate coding.
CIN 1 indicates mild dysplasia, CIN 2 indicates moderate dysplasia, and CIN 3 indicates severe dysplasia, with increasing risk of progression to cervical cancer.
Women should begin screening at age 21 and continue every three years until age 29. From ages 30 to 65, they may choose to have a Pap smear alone every three years or a Pap smear plus HPV testing every five years.
